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doi:10.1016/j.ejvs.2009.07.021Abstract Objectives: Leucocyte infiltration in the wall of varicose veins has been reported
previously. This study was designed to investigate the expression of pro-inflammatory cyto-
kines and chemokines in control and in patients with varicose veins and to test the effect of
treating varicose vein patients with acetylsalicylic acid (ASA) on cytokine expression prior to
removal of varices.
Material and methods: Sections of vein were removed during operation from both patient
groups, and ribonuclease protection assays (RPAs) were performed to assess the expression
of chemokines. Group I included non-varicose saphenous veins from healthy patients under-
going amputation for trauma. Varicose veins were obtained from patients with primary vari-
cose undergoing surgical treatment who received no drug (group II) or treatment with
300 mg day1 of ASA for 15 days before surgery (group III).
Results: Non-varicose veins constitutively expressed low levels of monocyte-chemoattractant
protein (MCP-1) and interleukin (IL)-8 mRNA. Varicose veins had a distinct chemokine expres-
sion pattern, since significant up-regulation of MCP-1 and IL-8 and a marked expression of
IP-10, RANTES, MIP-1a and MIP-1b mRNA were detected. Removal of the endothelium did
not alter this pattern. Varicose veins obtained from patients treated with ASA showed a consis-
tent decrease in chemokine expression, although it did not reach statistical significance.
Conclusions: Varicose veins showed increased expression of several chemokines compared to
control veins. A non-significant reduction of activation was observed following treatment with
ASA for 15 days.
ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Biologı´a y Gene´tica Molec-
olid, Spain. Tel.: þ34 983 184
.es (C. Garcı´a-Rodrı´guez).
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The pathogenesis of chronic venous disease, a complex and
common pathology affecting the lower extremities andSociety for Vascular Surgery.
636 L. del Rio Sola´ et al.manifested by a range of conditions, including varicose
veins, trophic skin changes and venous ulcers, is still poorly
understood.1e4 Varicose veins, the most common form of
chronic venous disease, affect up to 30% of the population
in Western countries, and are usually slightly more common
in women.2,3 Chronic venous insufficiency (CVI) is charac-
terised by symptoms or signs produced by venous hyper-
tension as a result of structural or functional abnormalities
of veins.4 Incompetence of the venous valves, vein wall
remodelling (including changes in the endothelium, the
extracellular matrix and smooth muscle cells)3 and micro-
circulatory dysfunction are related not only to venous
hypertension, but also to a cascade of biochemical events
that contribute to the progression of the disease.1e3
Significant progress has been made in understanding the
role of inflammation as a mechanism underlying the phys-
iopathology of chronic venous disease.2 The most widely
accepted mechanism linking venous hypertension to the
changes in the macro-and microcirculation is the leucocyte
‘trapping’ hypothesis, according to which, leucocytes
infiltrate the venous wall and valves due to their migration
across the post-capillary venules endothelium, thus
provoking valvular destruction and wall remodelling.2,5,6
Leucocytes may leave the circulation due to an incipient
inflammatory focus in the vascular intima or media,
because of the activation of endothelial cells by hypoxia,7
or by altered haemodynamics, that is, decreasing or
abnormal shear stress at specific points in the venous
circulation.8 In addition, fluid shear stress can control the
activation of leucocytes,9 and the response can be
enhanced by nitric oxide donors and suppressed by
inflammatory mediators.10 At the molecular level, several
reports have shown the involvement of inflammatory
molecules such as adhesion molecules and cytokines in
varicose vein disease.2
Chemokines are low-molecular-weight secreted cyto-
kines not only involved in leucocyte chemoattraction, but
are also implicated in the regulation of angiogenesis,
fibrosis and cell proliferation.11e13 Given the association of
increased recruitment of leucocytes to varicose veins,6 our
study was designed to address the pattern of expression of
chemokines in control and patients with varicose veins by
measuring the mRNA levels of several chemokines. Since we
had observed that acetylsalicylic acid (ASA) treatment of
patients with varicose syndrome accelerated healing and
delayed recurrence of venous ulceration,14 we also evalu-
ated the possible impact of an anti-inflammatory treatment
on chemokine expression.
Materials and Methods
Study design
A double-blind, parallel-group, randomised study was con-
ducted. Patients with symptomatic varicose veins were
randomly assigned, using a computer-based random
assignment program, to ASA treatment for 15 days or no
pharmacological treatment before surgery. Informed
written consent was obtained from all patients. The Insti-
tutional Review Board and Ethical Committee from
University Hospital approved the study protocol.Patients
Patients with symptomatic primary varicose veins due to
incompetence of the great saphenous vein were randomly
selected to obtain an even representation of variables and
were distributed in two groups. Before surgery, a duplex
ultrasound scan was performed in our vascular laboratory
by a qualified independent vascular surgeon. The CEAP
classification of the American Venous Forum for chronic
lower-extremity venous disease,15 based on clinical,
aetiological, anatomical and pathophysiological data, was
applied before varicose removal according to the physical
examination and haemodynamic findings.
Three different types of venous samples were surgically
removed. Group I (control, nZ 7) comprised non-varicose
saphenous veins, as judged by clinical examination, har-
vested from healthy patients with no history of venous
disease, undergoing amputation of the lower extremity as
a result of trauma. None was taking aspirin as antiplatelet
therapy, which is frequently the case when saphenous
venous are taken from patients undergoing coronary artery
bypass surgery. Vein specimens were harvested no more
than 6 h after trauma to the limb. Group II (varicose veins,
nZ 24) included varicose veins obtained by saphenous
stripping in patients not receiving antiplatelet therapy.
Group III (ASA-treated varicose veins, nZ 22) consisted of
varicose veins obtained by saphenous stripping in patients
treated with 300 mg day1 of ASA for 15 days prior to
surgery. In each case, specimens included saphenous veins
from the thigh. Valvular incompetence of the superficial
and perforating veins and competence of the deep venous
system had been confirmed preoperatively by duplex
ultrasonic scanning. All patients participating in the study
were undergoing compression therapy. Patients who had
a contraindication to ASA therapy or were under treatment
with other drugs such as non-steroid anti-inflammatory
drugs, antiplatelet drugs or had contraindication for its use,
that is, allergic reaction, were excluded from the study.
Tissue samples
After surgical removal, all vein specimens were snap-frozen
in dry ice and stored at 80 C until use. In some samples,
a venous segment was prepared by removing the endothe-
lial layer by gently rubbing the intimal surface with the tip
of small forceps, as described.16 The endothelium-free
segment was frozen, and endothelial cells were seeded into
gelatine-coated culture dishes and cultured in Medium 199
supplemented with antibiotics, 2 mM glutamine and 10%
foetal calf serum. All procedures followed were in accor-
dance with institutional guidelines.
Reagents
TRIzol reagent and cell culture media and supplements were
purchased from Invitrogen (San Diego, CA, USA). In vitro
translation and RiboQuant multiprobe kits and the hCK5 mul-
tiprobe were purchased from BD Pharmingen (Franklin Lanes,
NJ, USA). Uridine 50-[a-32P] triphosphate, triethylammonium
salt (3000 Ci mmol1, 10 mCi ml1) was purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK).
Table 1 Patient demographics and clinical risk factors.
Non-ASA treated
varicose vein
ASA treated
varicose vein
P
Age, SD (years) 51 SD 13 48 SD 15 0.42
Male:female (17:29) 9:15 8:14 0.79
CVI grade:
C2 10 8 0.83
C3 10 10
C4 3 3
C5eC6 1 1
Risk factors:
None (nZ 28) 13 15 0.73
Hypertension (nZ 5) 2 3
DM (nZ 2) 1 1
Cardiopathy (nZ 3) 2 1
Cardiopathy and DM
(nZ 1)
1 0
Hyperthyroidism (nZ 3) 2 1
Dyslipidemia (nZ 1) 1 0
Thrombopenia (nZ 1) 1 0
Hydatidic cyst (nZ 1) 0 1
COPD and neoplasia
(nZ 1)
1 0
SD, standard deviation; DM, diabetes mellitus; COPD, chronic
obstructive pulmonary disease. P values compare untreated to
treated varicose veins.
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Total RNA from each vein was extracted with TRIzol reagent
following the manufacturer’s standard protocol and was
performed in an RNase-free environment. Briefly, after
removal of adherent connective tissue, saphenous vein
segments were weighed, minced with a razor blade and
homogenised in 1 ml of TRIzol reagent per 100 mg of tissue
using a glass-Teflon homogeniser. After phenol-chloroform
extraction, total RNA was precipitated with isopropyl
alcohol and dissolved in 0.1% diethylpyrocarbonate (DEPC)-
water. RNA quantity and purity were estimated by
measuring the absorbance at 260 and 280 nm in a Spectro-
photometer Uvikon (Kontron, Eching, Germany). Once
collected, RNA was stored at 80 C until use.
Chemokine expression analysis by ribonuclease
protection assays (RPA)
mRNA levels were assessed by RPA, a highly sensitive
technique that allows simultaneous detection and quanti-
fication of several mRNAs, using the hCK5 multiprobe con-
taining probes that can hybridise with target mRNA
encoding the chemokines lymphotactin, RANTES, inter-
feron-g-inducible protein (IP)-10, macrophage-inflamma-
tory protein (MIP)-1a, MIP-1b, monocyte-chemoattractant
protein (MCP-1), IL-8 as well as the housekeeper genes L32
and GAPDH, as described earlier.17 The [32P]-radiolabelled
probe was hybridised in molar excess to target RNA in
solution, followed by digestion with RNases A and T1.
Samples were purified and resolved on denaturing poly-
acrylamide gels according to their size. Transcripts were
imaged by autoradiography and the signal intensity of each
band was quantified by densitometry scanning using a Bio-
Rad personal molecular imager FX. Results were normalised
to the values of the corresponding housekeeper genes L32
and GAPDH, which are internal controls that allow the
comparison of individual mRNA species between samples.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS) software version
14.0. Before the trial, we estimated that a sample of at
least 21 patients allocated in each group was required to
detect a variation of chemokine gene expression of 10%,
with 90% power at a significance level of 0.05. Data were
analysed by c2 test (qualitative variables such as sex, grade
of venous insufficiency and risk factors) and by Student’s
t-test (quantitative variables such as age and mRNA levels,
which showed a normal distribution of the mean in a Kol-
mogoroveSmirnoveLilliefors test).
Results
Patient demographics and clinical characteristics
Demographics andcharacteristics of thepatientsavailable for
clinical investigations are summarised in Table 1. Varicose
vein patients had incompetence of the saphenofemoral
junction combined with superficial and perforator reflux(Hawaii CEAP classification: C2e5, Ep, As and Pr). The
demographics for the control group were mean age 66 SD
16 years and the ratio of men to women was 3:4. No differ-
ences indemographics between the threegroupswere shown.
Non-varicose veins are characterised by
constitutive low expression of chemokines
MCP-1 and IL-8
To analyse chemokine expression in control veins, we per-
formed RPAs with veins from group I. As shown in the left
panel of Fig. 1A, low levels of mRNA encoding MCP-1 and IL-
8 were detected in non-varicose (control) veins. Notably,
no mRNA transcripts for other chemokine genes were
detected, that is, RANTES, IP-10, MIP-1a and MIP-1b
(Fig. 1A, left panel). Densitometry analysis revealed that
MCP-1 mRNA levels were 2.4 times higher than IL-8 levels
(Fig. 1B). Although some variations between individuals
were observed, the expression pattern was similar in every
vein tested (nZ 7). Altogether, our data identify a consti-
tutive low expression of the mRNA of the chemokines MCP-1
and IL-8 as a characteristic of non-varicose veins.
Elevated expression of chemokines is a feature of
varicose veins
RPAs revealed a distinct chemokine expression pattern in
varicose veins, characterised by a marked expression of all
the chemokines tested (Fig. 1A, right panel). Lymphotactin
was not expressed in veins. Detection of mRNAs encoding
the chemokines RANTES, IP-10, MIP-1a, MIP-1b, MCP-1 and
IL-8, and a significant rise in the expression of mcp-1 and
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Figure 1 Different patterns of chemokine mRNA expression
in non-varicose and varicose veins. (A) RNA was analyzed as
described in the methods section. The image is representative
of nZ 7 control (left panel) and nZ 24 varicose veins (right
panel). (B) Densitometry analysis of corresponding chemokine
transcripts normalized to the levels of housekeeper genes.
Data representing relative chemokine expression in arbitrary
units are expressed as mean and standard deviation. *Indicates
P  0.05.
638 L. del Rio Sola´ et al.il-8 genes as compared with control veins, was observed in
varicose veins (Fig. 1A, right panel). The densitometry data
from all the veins tested, normalised to internal control
genes, are summarised in Fig. 1B. Despite individual vari-
ations, the same expression pattern was observed in all of
the specimens tested. Together, these results showed
a marked expression of chemotactic cytokines associated
with venous disease, and a very distinct pattern as
compared with control veins, consistent with reports
showing higher leucocyte infiltration in varicose than in
control veins.18Removal of endothelium from varicose veins does
not alter the pattern of expression of chemokines
We investigated whether the endothelium might account
for the elevated chemokine expression levels in varicose
veins. For this purpose, specimens from untreated varicose
veins were used. The first intended approach was endo-
thelium removal followed by in vitro culture of the cells for
weeks to get enough RNA material; unfortunately this was
not followed by success since few cells were able to adhere
to the gelatin-precoated dishes, thus suggesting that vari-
cose vein endothelial cells had their adhesion properties
altered. When comparing endothelium-free and complete
wall veins, no significant differences in the levels of che-
mokines were observed (Fig. 2A), as the expression ratio of
endothelium-free vein/complete wall vein was close to 1
(Fig. 2B). These results suggest that endothelial cells are
not the main source of chemokines in varicose veins, even
though a complete removal of endothelial cells from the
vein wall might not have been achieved.
ASA treatment promoted a statistically insignificant
decrease of chemokine expression
We also investigated whether the treatment of patients
with ASA for 2 weeks before surgery had any impact on
chemokine expression, since in a separate study, we had
observed accelerated healing and delayed recurrence of
venous ulceration in patients treated with ASA (300 mg
day1 during the healing process),14 and because of the
association of increased recruitment of leucocytes to vari-
cose veins6 and the inhibition of some pro-inflammatory
cytokines by salicylates.17 A representative autoradiogram
comparing veins from untreated and treated patients is
shown in Fig. 3A. Densitometry analysis revealed a slight
decrease of all the chemokines after treatment with ASA,
since the mean of each chemokine was lower in treated
patients than in untreated patients (Fig. 3B). However, due
to the small amount of reduction and the variability
between patients, the decrease is not statistically
significant.
Discussion
The pathogenesis of varicose veins is not yet well under-
stood. This study shows for the first time a high level of
chemokine mRNA expression as a hallmark of varicose
veins, thus suggesting a potential role for chemokines in the
pathogenesis of this disease.
We have found that control veins constitutively express
low levels of MCP-1 and IL-8, cytokines known to attract
monocytes and neutrophils, respectively, and to be
expressed by endothelial cells, smooth muscle cells and
fibroblasts.11,12 Even though the number of control veins
was small due to the difficulty to get non-varicose saphe-
nous veins, the expression pattern was similar in every vein
tested. These results are consistent with reports showing
that normal veins have few infiltrating inflammatory cells.18
Our findings are reminiscent of what has recently been
reported for genes involved in extracellular matrix remod-
elling, since a differential expression of collagen III, tissue
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Figure 2 Chemokine expression pattern in varicose veins is
not altered by removal of endothelium. (A) RNA from complete
or endothelium-free varicose veins was tested. The autora-
diogram is representative of nZ 3 endothelium-free veins and
nZ 24 varicose veins. (B) Densitometry analysis was per-
formed as in Fig. 1.
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Figure 3 Chemokine expression shows a non-significant
downward trend in veins from patients treated with ASA. (A)
The autoradiogram is representative of nZ 24 varicose veins
from untreated patients (left panel) and nZ 22 of patients
treated with ASA (right panel). (B) Densitometry analysis was
performed as in Fig. 1.
Increased Chemokine Expression in Varicose Veins 639inhibitor of metalloproteinases I, dermatopontin, matrix
Gla protein and tenascin C in control versus patients with
varicose veins was observed.16 Our results provide evidence
of a marked expression of MCP-1, IL-8, MIP-1a, MIP-1b,
RANTES and IP-10 in varicose veins, suggesting that che-
mokines might play an important role in their pathophysi-
ology by recruiting leucocytes to the vein wall and
contributing to inflammation and oedema. It is well known
that MCP-1 (CCL2 in the new nomenclature), MIP-1a (CCL3),
MIP-1b (CCL4) and IP-10 are chemoattractants for mono-
cytes/macrophages, IL-8 (CXCL8) is able to attractneutrophils and RANTES (CCL5) is a chemotactic molecule
for leucocytes.11e13 Our results are consistent with several
reports showing association of marked leucocyte infiltration
to varicose venous disease.2,18,19 It is known that venous
hypertension activates endothelium and facilitates leuco-
cyte adhesion.20 Mast cell infiltration has been found in
preoperative and punch biopsies21 and in familial varicose
veins.22 Macrophage clusters and T lymphocytes have been
detected in varicose veins18 and monocytes in venous
valves.23 In addition, inappropriate neutrophil activation
occurs in venous disease.24
The present study links over-expression of pro-inflam-
matory molecules to varicose disease. Several groups have
demonstrated the association of other inflammatory medi-
ators to venous disease.2 Varicose veins express a variety of
640 L. del Rio Sola´ et al.adhesion molecules such as intercellular adhesion molecule
(ICAM)-1, vascular cellular adhesion molecule (VCAM)-1,
lymphocyte-function antigen, very late activation antigen-
4 and CD38.20,25,26 They also express cytokines such as
tumour necrosis factor, IL-1a and transforming growth
factor (TGF)-b1, a protein up-regulated in ageing varicose
veins and involved in the hypertrophy of the venous
wall.27e29 Other molecules such as metalloproteinases are
implicated in venous wall remodelling and used as markers
for blood stasis.30,31
Our experimental approach does not discriminate
between the possibilities that increased chemokine
expression is due to infiltrating leucocytes or originating
from resident cell populations. Cellular candidates
accounting for elevated chemokine expression include
fibroblast and smooth muscle cells, known to express IL-8,
and MCP-1, respectively, and infiltrating cells such as
monocytes/macrophages, which secrete MCP-1, MIP-1b and
a and IP-10 or lymphocytes, which produce RANTES.12
Endothelial cells, known to express MCP-1, IL-8 and IP-10,
likely are not the source of increased chemokines since
their removal does not alter the chemokine expression
pattern in varicose veins. However, our technique might
result in incomplete endothelial removal so some uncer-
tainty remains over the reliability of this conclusion.
Understanding the pathophysiology of chronic venous
disease is important to establish pharmacological
approaches that could complement current treatments.
Our results show a non-significant effect using anti-inflam-
matory drugs to diminish chemokine expression and,
consequently, leucocyte recruitment in the varicose vein.
Higher doses of ASA may have been more effective. Dosage
selection was based on a study showing accelerated healing
and delayed recurrence of venous ulceration in patients
treated with 300 mg day1 ASA during the healing
process.14 However, this dose is lower than that used for
inflammatory diseases and required for reduction of che-
mokine expression in vitro.17 Another possibility is that the
duration of treatment was insufficient to achieve a signifi-
cant effect. To date, several drugs that improve venous
tone and capillary permeability by unknown mechanisms
have been used for the treatment of chronic venous insuf-
ficiency, for example, a-benzopyrones, coumarins and
flavonoids, saponosides and other plant extracts.1 Animal
model studies have suggested that inhibition of the early
stages of inflammation offers a potential target for
pharmacological treatment of venous disease.32
In summary, this study has shown an association
between elevated levels of chemoattractant cytokines and
varicose veins. Pharmacological therapy aimed at reducing
cytokine expression may have a role in the management of
venous diseases in the future.
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